This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation
Clinical Epigenetics Open Access 12 October 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Mrozek K, Dohner H, Bloomfield CD . Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol 2007; 14: 106–114.
Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.
Miller CA, Wilson RK, Ley TJ . Genomic landscapes and clonality of de novo AML. N Engl J Med 2013; 369: 1473.
Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366: 1079–1089.
Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010; 17: 13–27.
Deneberg S, Guardiola P, Lennartsson A, Qu Y, Gaidzik V, Blanchet O et al. Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood 2011; 118: 5573–5582.
Hock H . A complex Polycomb issue: the two faces of EZH2 in cancer. Genes Dev 2012; 26: 751–755.
Shih AH, Abdel-Wahab O, Patel JP, Levine RL . The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12: 599–612.
Li B, Carey M, Workman JL . The role of chromatin during transcription. Cell 2007; 128: 707–719.
Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106: 3747–3754.
Vassiliou GS, Cooper JL, Rad R, Li J, Rice S, Uren A et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet 2011; 43: 470–475.
Valk PJ, Delwel R, Lowenberg B . Gene expression profiling in acute myeloid leukemia. Curr Opin Hematol 2005; 12: 76–81.
Marzluff WF, Wagner EJ, Duronio RJ . Metabolism and regulation of canonical histone mRNAs: life without a poly(A) tail. Nat Rev Genet 2008; 9: 843–854.
Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012; 109: 3879–3884.
Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298–303.
Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45: 242–252.
Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K . Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20: 1123–1136.
Acknowledgements
We thank Anne-Marie Imbert for the help with primary cells; all the Duprez Lab personnel for helpful discussions and the onco-genomic facility at IPC for microarray analysis. This work was supported by the Fondation de France grants 2008002092 and 201200029166, by the Laurette Fugain grants ALF 08/04 and 09/08, by the Fondation pour la Recherche Médicale (FRM) grant INE201000518534 and by the SIRIC leukemia program (INCa-DGOS-Inserm 6038). GT was supported by the FRM and Cancéropole PACA. AP was supported by Marie Curie research training fellowship (MRTN-CT-2006-035733) and the FRM. Samples of human origin and associated data were obtained from the IPC/CRCM Tumor Bank (Biological Resource Centre in Oncology), that operates under authorization #AC-2007-33 granted by the French Ministry of Research (Ministère de la Recherche et de l’Enseignement Supérieur). This paper presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (grant RP-PG-0108-10093, supporting DG and AI). This work was enabled by the NIHR Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London.
Disclaimer
The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Tiberi, G., Pekowska, A., Oudin, C. et al. PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia. Leukemia 29, 1202–1206 (2015). https://doi.org/10.1038/leu.2014.339
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.339